• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Preventing Infection: Optimizing Antibiotic Regimen Post- C-Section in Obese Women

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Data on perioperative antibiotic prophylaxis in obese women undergoing cesarean section is limited 
  • Valent et al. (JAMA, 2017) sought to determine rates of surgical site infection (SSI) among obese women who received prophylactic oral cephalexin and metronidazole vs placebo for 48 hours post surgery 

METHODS: 

  • Randomized, double-blind clinical trial (RCT) 
  • Women with prepregnancy BMI ≥30 were included in this study  
  • All women received standard preop cephalosporin prophylaxis  
  • Two arms of the study  
    • Oral cephalexin (500 mg) and metronidazole (500 mg) group administered every 8 hours for total 48 hours post-surgery 
    • Identical-appearing placebo 
  • Randomization was stratified by intact vs ruptured membranes
  • Primary outcome was SSI, defined as any superficial incisional, deep incisional, or organ/space infection within 30 days post-surgery 

RESULTS: 

  • 403 randomized participants completed the trial  
  • Mean age, 28 (SD, 6) years 
  • Mean BMI, 39.7 (SD, 7.8)  
  • Overall rate of SSI was 10.9% (95% CI 7.9%-14.0%) 
  • SSI was diagnosed in 13 women (6.4%) in the cephalexin-metronidazole group vs 31 women (15.4%) in the placebo group 
    • Difference, 9.0% (95% CI, 2.9%-15.0%) 
    • Relative risk, 0.41 (95% CI, 0.22-0.77; P = .01) 

CONCLUSION: 

  • A postoperative 48-hour course of oral cephalexin and metronidazole reduced the rate of SSI within 30 days after delivery 
  • This study supports the administration of prophylactic oral cephalexin and metronidazole for obese women after cesarean delivery 

Learn More – Primary Sources  

Effect of Post-Cesarean Delivery Oral Cephalexin and Metronidazole on Surgical Site Infection Among Obese Women: A Randomized Clinical Trial. 

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Best Antibiotic Strategy to Prevent Infection After Hysterectomy
Plastic-Sheath Wound Retractors Decrease C-Section Infection
Chlorhexidine or Povidone-Iodine for abdominal hysterectomy?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site